Taxanes in lung cancer therapy

Author(s)

Bibliographic Information

Taxanes in lung cancer therapy

edited by David H. Johnson, Jean Klastersky

Marcel Dekker, c1998

Available at  / 1 libraries

Search this Book/Journal

Note

Includes bibliographical references and index

Description and Table of Contents

Description

Exploring topics from pharmacokinetics and tubulin targets to schedule dependence and clinical toxicity profiles, this timely work compiles-in a single source-current information on taxanes and their superior activity against small-cell and non-small-cell lung cancer that will enable researchers to optimize present and future palliative and curative strategies. Representing international efforts to define the full potential of these chemotherapeutic drugs, Taxanes in Lung Cancer Therapy furnishes results from ongoing studies involving novel mechanisms of action for paclitaxel and docetaxel paclitaxel exposure duration as well as drug combinations and sequences phase II trials with paclitaxel in chemotherapy-naive advanced non-small-cell lung cancer (NSCLC) patients the combination of paclitaxel and other active agents, such as cisplatin and ifosfamide, in previously untreated small-cell lung cancer (SCLC) as well as advanced NSCLC comparisons of survival duration, response rates, and toxicity between taxol and other regimens the activity of docetaxel against platinum-resistant/refractory NSCLC and much more! Written by researchers and clinicians at the forefront of the field, Taxanes in Lung Cancer Therapy is an essential resource for oncologists, pulmonologists, cancer researchers, pharmacologists, research and development personnel in the pharmaceutical industry, and graduate and medical school students in these disciplines.

Table of Contents

Taxanes: New Insights into Mechanisms of Drug Action, John J. Wright, Ellen G. Feigal, and Susan G. Arbuck In Vitro Testing of Paclitaxel and Docetaxel Against Human Lung Cancer Cell Lines: Implications for Clinical Trials, Mark S. Georgiadis and Bruce E. Johnson Phase II Trials with Paclitaxel in Non-Small-Cell Lung Cancer: North American Experience, Alex Y. Chang Phase II Results of Taxanes in Lung Cancer: European Experience, Thomas Cerny and A. Calderoni Paclitaxel in the Treatment of Small-Cell Lung Cancer: North American Experience, David S. Ettinger Taxanes in Small-Cell Lung Cancer: European Experience, Nick Thatcher, M. Ranson, G. Jayson, and H. Anderson Phase III Experience with Paclitaxel in Non-Small-Cell Lung Cancer: North American Experience, Philip Bonomi, KyungMann Kim, and David H. Johnson Phase III Experience wtih Paclitaxel in Non-Small-Cell Lung Cancer: European Experience, Klaus Havemann and Martin Wolf Docetaxel Trials in Non-Small-Cell Carcinoma of the Lung, Richard J. Gralla Single-Agent Paclitaxel as Second-Line Chemotherapy for Resistant, Metastatic Non-Small-Cell Lung Cancer, Linda L. Garland, John C. Ruckdeschel, Henry Wagner, Jr., Charles C. Williams, Jr., Gail Shaw, Scott J. Antonia, Mary Heise, Jane Hilstro, and Alan Cantor Docetaxel in Chemotherapy-Refractory or Recurrent Non-Small-Cell Lung Cancer, Frank V. Fossella, Jin Soo Lee, and Waun Ki Hong Paclitaxel: Combinations with Cisplatin or Carboplatin in Non-Small-Cell Lung Cancer, Chandra P. Belani Paclitaxel/Cisplatin Combination in Operable Non-Small-Cell Lung Cancer: European Experience, O. Rixe, L. Belli, J. P. Sculier, Jean Klastersky, and T. LeChevalier Taxanes in Lung Cancer: Combinations of Paclitaxel and Ifosfamide in Non-Small-Cell Lung Cancer, Ann M. Mauer, Philip C. Hoffman, Gregory A. Masters, Harvey M. Golomb, and Everett E. Vokes Taxanes and Radiation Therapy in Solid Tumors, Hak Choy, W. Akerley, and H. Safran

by "Nielsen BookData"

Details

Page Top